Spexis AG
Develops therapeutics for rare diseases, oncology, and antimicrobial resistance.
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Manufacturing
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for rare diseases and oncology. The company leverages its expertise in macrocycle technology to create novel drug candidates designed to address high unmet medical needs. Its pipeline is advanced through a strategy that includes in-house discovery, development, in-licensing, and the acquisition of promising molecules. The primary therapeutic areas of interest include rare diseases and cancer, with an additional focus on antimicrobial resistance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-04-12 07:00 |
Polyphor's antibiotic murepavadin receives US FDA Qualified Infectious Disease …
|
English | 9.7 KB | ||
| 2019-04-09 07:00 |
Polyphor appoints Gokhan Batur as Chief Commercial Officer
|
English | 9.2 KB | ||
| 2019-04-04 07:00 |
Polyphor to present data on murepavadin and its lead preclinical compound of it…
|
English | 10.1 KB | ||
| 2019-03-15 07:00 |
Polyphor announces financial results for the full-year 2018
|
English | 19.5 KB | ||
| 2019-02-04 18:00 |
Polyphor awarded grant from CARB-X of up to $5.6M to support development of nov…
|
English | 9.1 KB | ||
| 2018-12-03 07:00 |
Polyphor announces positive results from the FDA Type B Guidance meeting on the…
|
English | 10.3 KB | ||
| 2018-11-23 07:00 |
Polyphor wins the Swiss Technology Award 2018
|
English | 7.8 KB | ||
| 2018-10-24 07:05 |
Balixafortide combination with eribulin in metastatic breast cancer data presen…
|
English | 10.6 KB | ||
| 2018-10-24 07:00 |
Polyphor announces protocol agreement with the FDA for the second pivotal Phase…
|
English | 9.6 KB | ||
| 2018-10-24 06:56 |
CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition
|
English | 7.0 KB | ||
| 2018-10-18 17:31 |
Polyphor to present new survival data for balixafortide at the 2018 European So…
|
English | 9.7 KB | ||
| 2018-09-06 07:00 |
Polyphor announces financial results for the first half 2018
|
English | 16.5 KB | ||
| 2018-09-06 06:45 |
Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the development…
|
English | 10.0 KB | ||
| 2018-07-17 07:00 |
Polyphor announces listing of new shares related to the convertible loan facili…
|
English | 5.3 KB | ||
| 2018-04-30 07:00 |
Polyphor announces publication of positive proof of concept data for innovative…
|
English | 11.8 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Spexis AG
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
Peer Companies
